Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial. Bergen, … Read more
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 Increasing confidence in bemcentinib safety profile with more than 250 patients dosed Bergen, Norway, 12 February 2019 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple … Read more
Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, … Read more
Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib (BGB324) Advanced lung cancer (NSCLC): First stage fully recruited, and first efficacy endpoint met in phase II trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® Advanced leukaemia (AML/MDS): Encouraging bemcentinib single agent activity in hard to treat relapsed / refractory (R/R) leukaemia … Read more
Bergen, Norway, 15 May 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, … Read more
Bergen, Norway, 13 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2017. A presentation of the results by the Company’s senior management team will take place today at 10.00 am CET in … Read more
Bergen, 13. februar 2018 – BerGenBio ASA (OSE: BGBIO), et onkologisk bioteknologiselskap i klinisk fase som utvikler ‘first-in-class’ hemmere av Axl kinase mot flere krefttyper, offentliggjør resultatet for fjerde kvartal 2017 og for året som helhet.Selskapets ledelse vil avholde en presentasjon i Oslo i dag klokken 10. Detaljer følger nedenfor.Kommentar fra administrerende direktør Richard Godfrey:«BerGenBio … Read more
Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the third quarter 2017. A presentation of the results by the Company’s senior management team will take place today at 9.00 am CET in Oslo – details … Read more
Bergen, Norway, 18 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the second quarter and half year 2017. A presentation of the results by the Company’s senior management team will take place today at 10.00 am CEST in Oslo – … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.